Scientists probe why obese people may handle thirst differently
NCT ID NCT01224704
First seen Jun 27, 2026 · Last updated Sep 17, 2026 · Updated 6 times
Summary
This completed study looked at how lean and obese individuals respond to thirst and water deprivation. Researchers gave 75 healthy men a high-salt infusion and a 24-hour water fast, measuring their thirst, hormone levels, and water intake. The goal was to understand if body fat affects water balance, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
75 people
The number who actually took part.
- Started
-
Oct 2010
- Finished
-
Mar 2019
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Male. * Age 18-50 yrs to minimize hormonal influences on thirst perception in aging men. * BMI\<25 kg/m\^2 for the lean group and BMI \>=35 kg/m\^2 for obese group (but weigh less than 350 pounds to accommodate the DXA scanner) for the obese group. * Healthy, as determined by medical history and physical examination, without the exclusions listed below: EXCLUSION CRITERIA: History or Clinical Manifestation of: * Currently smoking * Any medications * Weight \<50kg (as the blood withdrawal limit would be exceeded) * Hemoglobin concentration \< 12mg/dl on screening labs * Type 1 or type 2 diabetes (according to World Health Organization diagnostic criteria (59)) * Endocrine disorders (Cushing's disease, pituitary diseases, hypo- or hyperthyroidism, diabetes insipidus, SIADH) * Hypertension as diagnosed and treated by an outside physician or by sitting blood pressure measurement, using an appropriate cuff, \>140/90 mmHg on two or more occasions * Fasting triglyceride concentrations \>= 500 mg/dl * Cardiovascular disease, including coronary heart disease, heart failure, arrhythmias and peripheral arterial disease * Liver disease, including cirrhosis, active hepatitis B or C and AST or ALT \>= 3x normal * Renal disease, as defined by serum creatinine concentrations \>= 1.5 mg/dl and / or proteinuria \>300 mg/day (200 (micro)g/min) * Central nervous system disease, including previous history of cerebrovascular accidents, dementia, and neurodegenerative disorders * Cancer requiring treatment in the past five years, except for non-melanoma skin cancers or cancers that have been clearly cured or, in the opinion of the investigator, carry an excellent prognosis * Infectious diseases such as active tuberculosis, HIV (by self report), chronic coccidioidomycoses or other chronic infections * Alcohol and/or current use of drugs (more than 2 drinks per day and regular use of drugs such as amphetamines, cocaine, heroin, or marijuana) * Psychiatric conditions or behaviors that would be incompatible with safe and successful participation in this study, including claustrophobia and eating disorders such as anorexia or bulimia nervosa All subjects will be fully informed of the aim, nature, and risks of the study prior to giving written informed consent. Subjects will also be specifically advised that the results of testing for drug usage will be filed in the medical record and would, therefore, be available as part of this record.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NIDDK, Phoenix
Phoenix, Arizona, 85014, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?
- Can a cold cloth on the neck calm Post-Surgery nausea?